Silo Pharma (NASDAQ:SILO) Releases Quarterly Earnings Results, Misses Estimates By $0.44 EPS

Silo Pharma (NASDAQ:SILO) announced its quarterly earnings data on Thursday. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.44), FiscalAI reports. Silo Pharma had a negative net margin of 6,726.39% and a negative return on equity of 88.40%.

Silo Pharma Stock Performance

SILO stock traded up $0.06 on Friday, reaching $3.28. The company had a trading volume of 21,985 shares, compared to its average volume of 199,590. The company has a market cap of $4.10 million, a P/E ratio of -0.51 and a beta of 0.71. Silo Pharma has a 1 year low of $2.75 and a 1 year high of $15.15. The company’s fifty day moving average is $5.34 and its 200 day moving average is $5.57.

Institutional Trading of Silo Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the stock. DRW Securities LLC acquired a new stake in shares of Silo Pharma in the 4th quarter worth about $113,000. AdvisorShares Investments LLC raised its stake in shares of Silo Pharma by 64.3% in the 4th quarter. AdvisorShares Investments LLC now owns 599,507 shares of the company’s stock valued at $204,000 after acquiring an additional 234,629 shares in the last quarter. Virtu Financial LLC acquired a new stake in Silo Pharma in the 3rd quarter worth approximately $74,000. Finally, Geode Capital Management LLC grew its holdings in Silo Pharma by 134.6% during the fourth quarter. Geode Capital Management LLC now owns 92,905 shares of the company’s stock valued at $32,000 after purchasing an additional 53,309 shares during the last quarter. Institutional investors own 5.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Silo Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Silo Pharma currently has a consensus rating of “Sell”.

About Silo Pharma

Silo Pharma, Inc (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health.

The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents.